Payment overview · 2025
General Payments
$246.77
13 reported records · 10 companies
Healthcare provider profile · identity verified
William C Brown, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · CLEARWATER, FL · NPI 1396741088
Verified facts
What the public records show
CMS Open Payments records show William C Brown, M.D. received $246.77 in general payments during 2025 across 13 reported records.
Novo Nordisk Inc accounted for 21.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $51.92 | 21.0% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $37.96 | 15.4% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $31.41 | 12.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $24.07 | 9.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.61 | 7.5% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $17.93 | 7.3% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $17.07 | 6.9% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.73 | 6.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.96 | 6.5% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.11 | 6.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $246.77 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $51.92 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $33.20 | 2 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $31.41 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $30.73 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $24.07 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $24.07 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $22.34 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $22.34 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $18.61 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $18.61 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $17.93 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $17.07 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $16.73 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.96 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 52 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 52 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 35 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
52 | 14 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
35 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
52 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
101 | 20 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
27 | 27 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 563 | 140 |
| Amlodipine Besylate | Amlodipine Besylate | 368 | 102 |
| Losartan Potassium | Losartan Potassium | 358 | 97 |
| Atorvastatin Calcium | Atorvastatin Calcium | 355 | 114 |
| Lorazepam | Lorazepam | 267 | 53 |
| Meloxicam | Meloxicam | 265 | 71 |
| Metformin Hcl | Metformin Hcl | 233 | 65 |
| Pravastatin Sodium | Pravastatin Sodium | 230 | 62 |
| Omeprazole | Omeprazole | 219 | 61 |
| Pantoprazole Sodium | Pantoprazole Sodium | 217 | 56 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 210 | 66 |
| Gabapentin | Gabapentin | 199 | 57 |
| Tramadol Hcl | Tramadol Hcl | 195 | 37 |
| Lisinopril | Lisinopril | 193 | 54 |
| Montelukast Sodium | Montelukast Sodium | 176 | 48 |
| Trazodone Hcl | Trazodone Hcl | 175 | 49 |
| Tamsulosin Hcl | Tamsulosin Hcl | 157 | 39 |
| Zolpidem Tartrate | Zolpidem Tartrate | 152 | 29 |
| Alprazolam | Alprazolam | 146 | 32 |
| Simvastatin | Simvastatin | 139 | 40 |
| Hydrochlorothiazide | Hydrochlorothiazide | 133 | 43 |
| Citalopram Hbr | Citalopram Hydrobromide | 131 | 33 |
| Azithromycin | Azithromycin | 125 | 89 |
| Metoprolol Succinate | Metoprolol Succinate | 121 | 34 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 120 | 80 |
| Doxycycline Hyclate | Doxycycline Hyclate | 114 | 62 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 112 | 29 |
| Prednisone | Prednisone | 110 | 47 |
| Eliquis | Apixaban | 101 | 20 |
| Sertraline Hcl | Sertraline Hcl | 99 | 24 |
| Alendronate Sodium | Alendronate Sodium | 98 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 98 | 29 |
| Furosemide | Furosemide | 91 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 88 | 28 |
| Ropinirole Hcl | Ropinirole Hcl | 87 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 79 | 28 |
| Potassium Chloride | Potassium Chloride | 74 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 72 | 20 |
| Raloxifene Hcl | Raloxifene Hcl | 72 | 20 |
| Finasteride | Finasteride | 71 | 18 |
| Allopurinol | Allopurinol | 70 | 22 |
| Terazosin Hcl | Terazosin Hcl | 69 | 18 |
| Metformin Hcl Er | Metformin Hcl | 67 | 19 |
| Fluconazole | Fluconazole | 62 | 21 |
| Ezetimibe | Ezetimibe | 59 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 58 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 55 | 15 |
| Spironolactone | Spironolactone | 54 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 53 | 14 |
| Jardiance | Empagliflozin | 52 | 14 |
| Mounjaro | Tirzepatide | 52 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 50 | 12 |
| Acyclovir | Acyclovir | 49 | 23 |
| Celecoxib | Celecoxib | 48 | 14 |
| Dicyclomine Hcl | Dicyclomine Hcl | 48 | 12 |
| Memantine Hcl | Memantine Hcl | 47 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 47 | 25 |
| Atenolol | Atenolol | 46 | 15 |
| Xarelto | Rivaroxaban | 45 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 44 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 44 | suppressed |
| Synthroid | Levothyroxine Sodium | 42 | suppressed |
| Famotidine | Famotidine | 41 | 13 |
| Carvedilol | Carvedilol | 38 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 38 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 37 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 35 | 18 |
| Ibuprofen | Ibuprofen | 35 | 12 |
| Levofloxacin | Levofloxacin | 35 | 27 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 35 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 34 | 14 |
| Benazepril Hcl | Benazepril Hcl | 33 | suppressed |
| Cephalexin | Cephalexin | 33 | 22 |
| Metoclopramide Hcl | Metoclopramide Hcl | 33 | suppressed |
| Valsartan | Valsartan | 33 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 32 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 32 | 24 |
| Buspirone Hcl | Buspirone Hcl | 31 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 31 | suppressed |
| Amoxicillin | Amoxicillin | 30 | 18 |
| Diazepam | Diazepam | 30 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 30 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 30 | suppressed |
| Ozempic | Semaglutide | 30 | suppressed |
| Pregabalin | Pregabalin | 30 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 29 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 28 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 27 | 27 |
| Donepezil Hcl | Donepezil Hcl | 26 | suppressed |
| Irbesartan | Irbesartan | 26 | suppressed |
| Lovastatin | Lovastatin | 25 | suppressed |
| Bupropion Xl | Bupropion Hcl | 23 | suppressed |
| Temazepam | Temazepam | 23 | suppressed |
| Mirtazapine | Mirtazapine | 22 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 21 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 20 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 13 |
| Januvia | Sitagliptin Phosphate | 19 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 19 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 19 | suppressed |
| Clonazepam | Clonazepam | 18 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 18 | suppressed |
| Nitroglycerin | Nitroglycerin | 18 | 11 |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Zolmitriptan | Zolmitriptan | 17 | suppressed |
| Amoxicillin-Clavulanate Pot Er | Amoxicillin/Potassium Clav | 16 | suppressed |
| Demeclocycline Hcl | Demeclocycline Hcl | 16 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Eszopiclone | Eszopiclone | 16 | suppressed |
| Tradjenta | Linagliptin | 16 | suppressed |
| Ursodiol | Ursodiol | 16 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 15 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 13 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Repatha Syringe | Evolocumab | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Rivastigmine | Rivastigmine | 12 | suppressed |
| Ubrelvy | Ubrogepant | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Descovy | Emtricitabine/Tenofov Alafenam | 11 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Verapamil Sr | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $246.77 · 13 records | Novo Nordisk Inc | AIRSUPRA, AREXVY, CONTRAVE, Cologuard Collection Kit, FREESTYLE LIBRE 3, JARDIANCE, MOUNJARO, NURTEC ODT, Ozempic, Rybelsus, TRELEGY ELLIPTA, WATCHMAN Access System, ZAVZPRET, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error